United Therapeutics Corporation
UTHR
Price:
$363.65
Market Cap:
$16.23B
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unit...[Read more]
Industry
Biotechnology
IPO Date
1999-06-17
Stock Exchange
NASDAQ
Ticker
UTHR
PE Ratio
[15.98]
ROE
[19.22%]
Current Ratio
[4.58]
Dividend Yield
[0%]
Enterprise Value
[15.08B]
Dividend History
The ROE as of December 2024 (TTM) for United Therapeutics Corporation (UTHR) is 19.22%
According to United Therapeutics Corporation’s latest financial reports and current stock price. The company's current ROE is 19.22%. This represents a change of 297.93% compared to the average of 4.83% of the last 4 quarters.
United Therapeutics Corporation (UTHR) Historical ROE (quarterly & annually)
How has UTHR ROE performed in the past?
The mean historical ROE of United Therapeutics Corporation over the last ten years is 20.20%. The current 19.22% ROE has changed -4.85% with respect to the historical average. Over the past ten years (40 quarters), UTHR's ROE was at its highest in in the September 2015 quarter at 31.39%. The ROE was at its lowest in in the March 2019 quarter at -21.15%.
Average
20.20%
Median
18.17%
Minimum
-3.76%
Maximum
40.74%
United Therapeutics Corporation (UTHR) ROE by Quarter and Year
Discovering the peaks and valleys of United Therapeutics Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 100.78%
Maximum Annual ROE = 40.74%
Minimum Annual Increase = -503.43%
Minimum Annual ROE = -3.76%
| Year | ROE | Change |
|---|---|---|
| 2023 | 16.46% | 8.52% |
| 2022 | 15.16% | 26.16% |
| 2021 | 12.02% | -20.74% |
| 2020 | 15.16% | -503.43% |
| 2019 | -3.76% | -117.79% |
| 2018 | 21.13% | 6.27% |
| 2017 | 19.88% | -48.12% |
| 2016 | 38.33% | -5.92% |
| 2015 | 40.74% | 51.60% |
| 2014 | 26.87% | 100.78% |
United Therapeutics Corporation (UTHR) Average ROE
How has UTHR ROE performed in the past?
The current ROE of United Therapeutics Corporation (UTHR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
14.55%
5-year avg
11.01%
10-year avg
20.20%
United Therapeutics Corporation (UTHR) ROE vs. Peers
How is UTHR’s ROE compared to its peers?
United Therapeutics Corporation’s ROE is less than Incyte Corporation (0.78%), less than Alnylam Pharmaceuticals, Inc. (323.66%), greater than Ultragenyx Pharmaceutical Inc. (-187.12%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than Replimune Group, Inc. (-53.12%), greater than Nuvalent, Inc. (-28.63%), greater than Ventyx Biosciences, Inc. (-54.94%), less than Ascendis Pharma A/S (212.63%), greater than MannKind Corporation (-9.46%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Kiniksa Pharmaceuticals, Ltd. (-2.08%), greater than BeiGene, Ltd. (-25.12%), greater than Akero Therapeutics, Inc. (-32.52%), greater than Blueprint Medicines Corporation (-47.66%), greater than Vaxcyte, Inc. (-23.53%), greater than Legend Biotech Corporation (-29.69%),
| Company | ROE | Market cap |
|---|---|---|
| 0.78% | $13.45B | |
| 323.66% | $31.25B | |
| -187.12% | $4.05B | |
| -103.92% | $4.13B | |
| -53.12% | $929.70M | |
| -28.63% | $5.96B | |
| -54.94% | $166.17M | |
| 212.63% | $8.35B | |
| -9.46% | $1.94B | |
| -35.87% | $252.67M | |
| -22.40% | $1.28B | |
| -2.08% | $1.46B | |
| -25.12% | $19.62B | |
| -32.52% | $1.98B | |
| -47.66% | $5.74B | |
| -23.53% | $10.85B | |
| -29.69% | $6.22B |
Build a custom stock screener for United Therapeutics Corporation (UTHR) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like United Therapeutics Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
United Therapeutics Corporation (UTHR) and other stocks custom spreadsheet templates
The easiest way to analyze a company like United Therapeutics Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is United Therapeutics Corporation's ROE?
How is the ROE calculated for United Therapeutics Corporation (UTHR)?
What is the highest ROE for United Therapeutics Corporation (UTHR)?
What is the 3-year average ROE for United Therapeutics Corporation (UTHR)?
What is the 5-year average ROE for United Therapeutics Corporation (UTHR)?
How does the current ROE for United Therapeutics Corporation (UTHR) compare to its historical average?